Efficacy of Rifabutin-Based Helicobacter pylori Eradication Regimen in Korea With High Prevalence of Tuberculosis Infection

IF 4.3 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Helicobacter Pub Date : 2025-02-04 DOI:10.1111/hel.70011

Yuri Kim, Jeong Hoon Lee, Hee Kyong Na, Kee Wook Jung, Ji Yong Ahn, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung

{"title":"Efficacy of Rifabutin-Based Helicobacter pylori Eradication Regimen in Korea With High Prevalence of Tuberculosis Infection","authors":"Yuri Kim, Jeong Hoon Lee, Hee Kyong Na, Kee Wook Jung, Ji Yong Ahn, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung","doi":"10.1111/hel.70011","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>As the antibiotic resistance and treatment failure rates of <i>Helicobacter pylori</i> are rising, the need for rescue therapy with rifabutin for <i>H. pylori</i> eradication (HPE) is also increasing. Therefore, in this study, we investigated the efficacy, resistance status, and adverse events in patients receiving rifabutin-based HPE.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>Between January 2020 and December 2022, 3006 patients underwent esophagogastroduodenoscopy (EGD) with <i>H. pylori</i> culture tests. Of these, culture results were successfully obtained from 1792 patients, who were subsequently enrolled in our study. The medical records of these patients were retrospectively reviewed, and their clinical features and outcomes assessed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among the 1792 patients, 14 (0.8%) were rifabutin-resistant. A total of 665 (37.1%) patients had multidrug-resistant (MDR) <i>H. pylori</i> infections. Patients with rifabutin-resistant <i>H. pylori</i> infections had a significantly higher rate of tuberculosis treatment history (2.8% vs. 28.6%, <i>p</i> < 0.001) and MDR <i>H. pylori</i> infections (49.6% vs. 85.7%, <i>p</i> < 0.001) than those in the rifabutin-susceptible <i>H. pylori</i> group. Among the 45 patients who received the rifabutin-based HPE regimen, 44 (97.8%) had MDR <i>H. pylori</i> infection, and 35 (77.8%) underwent rifabutin-based HPE as a third-line treatment or beyond. A total of 31 (68.9%) showed successful eradication. Nineteen (42.2%) patients experienced at least one symptom of adverse events; however, the severity of side effects was mild, and no patient discontinued treatment because of this.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The rifabutin-based HPE regimen could be an effective and safe treatment method. It is particularly considered a viable therapeutic option for patients who require HPE but have previously failed to respond to multiple HPEs.</p>\n </section>\n </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 1","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Helicobacter","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hel.70011","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

As the antibiotic resistance and treatment failure rates of Helicobacter pylori are rising, the need for rescue therapy with rifabutin for H. pylori eradication (HPE) is also increasing. Therefore, in this study, we investigated the efficacy, resistance status, and adverse events in patients receiving rifabutin-based HPE.

Materials and Methods

Between January 2020 and December 2022, 3006 patients underwent esophagogastroduodenoscopy (EGD) with H. pylori culture tests. Of these, culture results were successfully obtained from 1792 patients, who were subsequently enrolled in our study. The medical records of these patients were retrospectively reviewed, and their clinical features and outcomes assessed.

Results

Among the 1792 patients, 14 (0.8%) were rifabutin-resistant. A total of 665 (37.1%) patients had multidrug-resistant (MDR) H. pylori infections. Patients with rifabutin-resistant H. pylori infections had a significantly higher rate of tuberculosis treatment history (2.8% vs. 28.6%, p < 0.001) and MDR H. pylori infections (49.6% vs. 85.7%, p < 0.001) than those in the rifabutin-susceptible H. pylori group. Among the 45 patients who received the rifabutin-based HPE regimen, 44 (97.8%) had MDR H. pylori infection, and 35 (77.8%) underwent rifabutin-based HPE as a third-line treatment or beyond. A total of 31 (68.9%) showed successful eradication. Nineteen (42.2%) patients experienced at least one symptom of adverse events; however, the severity of side effects was mild, and no patient discontinued treatment because of this.

Conclusions

The rifabutin-based HPE regimen could be an effective and safe treatment method. It is particularly considered a viable therapeutic option for patients who require HPE but have previously failed to respond to multiple HPEs.

查看原文本刊更多论文

以利福布汀为基础的幽门螺杆菌根除方案在韩国肺结核高发人群中的疗效

背景随着幽门螺杆菌耐药性和治疗失败率的上升，利法布汀对幽门螺杆菌根除（HPE）的抢救治疗需求也在增加。因此，在本研究中，我们调查了接受利法布汀类HPE的患者的疗效、耐药状况和不良事件。材料和方法在2020年1月至2022年12月期间，3006例患者接受了食管胃十二指肠镜检查（EGD）并进行了幽门螺旋杆菌培养试验。其中，成功获得了1792例患者的培养结果，这些患者随后被纳入我们的研究。回顾性回顾了这些患者的医疗记录，并评估了他们的临床特征和预后。结果1792例患者中，14例（0.8%）出现利法布汀耐药。665例（37.1%）患者存在多药耐药（MDR）幽门螺杆菌感染。耐利法布丁幽门螺杆菌感染患者的结核病治疗史（2.8%比28.6%,p < 0.001）和耐多药幽门螺杆菌感染（49.6%比85.7%,p < 0.001）均显著高于利法布丁敏感幽门螺杆菌组。在45名接受利法布汀HPE方案的患者中，44名（97.8%）患有耐多药幽门螺杆菌感染，35名（77.8%）接受了利法布汀HPE作为三线或以上治疗。31例（68.9%）成功根除。19例（42.2%）患者出现至少一种不良事件症状；然而，副作用的严重程度是轻微的，没有患者因此停止治疗。结论以利法布汀为基础的HPE方案是一种安全有效的治疗方法。对于需要HPE但先前多次HPE无效的患者，它被认为是一种可行的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Helicobacter 医学-微生物学

CiteScore

8.40

自引率

9.10%

发文量

审稿时长

2 months

期刊介绍： Helicobacter is edited by Professor David Y Graham. The editorial and peer review process is an independent process. Whenever there is a conflict of interest, the editor and editorial board will declare their interests and affiliations. Helicobacter recognises the critical role that has been established for Helicobacter pylori in peptic ulcer, gastric adenocarcinoma, and primary gastric lymphoma. As new helicobacter species are now regularly being discovered, Helicobacter covers the entire range of helicobacter research, increasing communication among the fields of gastroenterology; microbiology; vaccine development; laboratory animal science.